Ypsomed Holding AG (YPSN) AI Stock Analysis

• Market Cap: CHF4.28B
• Dividend Yield: 0.71%
• Average Volume (3M): 28.07K
• Price to Earnings (P/E): 48.5
• Beta (1Y): 0.68
• Revenue Growth: 36.54%
• EPS Growth: 11.60%
• Country: CH
• Employees: 2,600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 4.02
• Shares Outstanding: 13,649,739
• 10 Day Avg. Volume: 19,034
• 30 Day Avg. Volume: 28,071
• PEG Ratio: 4.54
• Price to Book (P/B): 6.82
• Price to Sales (P/S): 6.19
• P/FCF Ratio: -35.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF457.75
• Price Target Upside: 48.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 58 Neutral
• Price Target: CHF327.00 ▲(6.34% Upside)

Ypsomed Holding AG's strong financial performance is offset by bearish technical indicators and a high P/E ratio, suggesting potential overvaluation. The negative Free Cash Flow due to high capital expenditures is a concern, and the stock's downward trend further impacts its attractiveness.

Ypsomed Holding AG Business Overview & Revenue Model

Company Description

Ypsomed Holding AG is a Swiss-based company specializing in the development and manufacturing of injection and infusion systems for the self-medication of chronic diseases, particularly diabetes. The company's core products include insulin delivery systems, pens, and other injection-related devices, as well as services for the pharmaceutical industry. Ypsomed operates primarily in the medical technology sector, focusing on innovative solutions that enhance patient care and improve treatment adherence.

How the Company Makes Money

Ypsomed generates revenue through multiple key streams, primarily from the sale of its medical devices and systems for self-medication. This includes direct sales of insulin delivery devices to healthcare providers and pharmaceutical companies. Additionally, the company earns revenue from development partnerships with pharmaceutical firms, where it collaborates on the design and production of customized drug delivery systems. Ypsomed also benefits from recurring revenue through the sale of disposable components related to its delivery systems. Significant partnerships with major pharmaceutical companies further bolster its revenue by enabling co-development projects and expanding the market reach of its products.

Ypsomed Holding AG Financial Statement Overview

Summary

Ypsomed Holding AG shows strong revenue growth and profitability with effective cost management. The balance sheet is healthy with a reasonable debt-to-equity ratio and strong ROE. However, negative free cash flow due to high capital expenditures poses a risk.

Income Statement

Ypsomed Holding AG has demonstrated notable revenue growth, with Total Revenue increasing from CHF 548.5 million in 2024 to CHF 748.9 million in 2025, representing a growth rate of 36.54%. The company's Gross Profit Margin is robust at 39.00%, and the Net Profit Margin is healthy at 11.69%, reflecting strong profitability. EBIT and EBITDA Margins are also solid at 15.08% and 25.49%, respectively, indicating effective cost management and operational efficiency.

Balance Sheet

The company's Debt-to-Equity Ratio is 0.39, which indicates a reasonable level of leverage. The Return on Equity (ROE) is strong at 12.88%, showcasing effective utilization of shareholder funds. The Equity Ratio stands at 51.08%, highlighting a balanced capital structure with a significant portion funded by equity, contributing to financial stability.

Cash Flow

Ypsomed Holding AG's Free Cash Flow is negative at CHF -128.9 million, primarily due to high capital expenditures. However, the Operating Cash Flow to Net Income Ratio is favorable at 1.69, suggesting that the company's operations are generating sufficient cash relative to its net income. The Free Cash Flow to Net Income Ratio is negative, indicating challenges in converting net income into free cash flow, which might be a concern if sustained.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	374.43M	748.87M	548.46M	497.46M	464.84M	403.66M
Gross Profit	146.03M	292.07M	189.05M	140.59M	113.82M	94.83M
EBITDA	88.22M	190.90M	161.56M	137.51M	95.67M	63.86M
Net Income	43.75M	87.50M	78.37M	51.27M	23.11M	5.81M
Balance Sheet
Total Assets	1.33B	1.33B	1.10B	861.88M	756.91M	717.68M
Cash, Cash Equivalents and Short-Term Investments	36.49M	36.49M	74.02M	25.22M	17.04M	22.41M
Total Debt	267.00M	267.00M	256.00M	157.00M	267.00M	215.00M
Total Liabilities	650.66M	650.66M	483.66M	299.55M	364.37M	322.30M
Stockholders Equity	679.68M	679.68M	617.73M	562.33M	392.54M	395.38M
Cash Flow
Free Cash Flow	-28.70M	-128.95M	-32.09M	-39.64M	-41.72M	-40.75M
Operating Cash Flow	74.10M	148.20M	163.22M	129.53M	85.71M	85.83M
Investing Cash Flow	-267.27M	-267.27M	-195.07M	-122.02M	-125.70M	-106.91M
Financing Cash Flow	82.25M	82.25M	81.07M	1.26M	38.12M	26.67M

Ypsomed Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 307.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:YPSN, the sentiment is Negative. The current price of 307.5 is below the 20-day moving average (MA) of 321.55, below the 50-day MA of 361.37, and below the 200-day MA of 368.47, indicating a bearish trend. The MACD of -13.01 indicates Negative momentum. The RSI at 34.44 is Neutral, neither overbought nor oversold. The STOCH value of 64.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:YPSN.

Ypsomed Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOVE	―	$2.98B	33.23	23.83%	0.46%	16.59%	65.76%
SFZN	―	$3.54B	22.30	15.79%	0.48%	0.77%	16.70%
GALE	―	CHF4.39B	22.83	―	2.72%	5.84%	8.57%
ALC	―	$29.71B	31.40	4.98%	0.47%	1.60%	-4.40%
TECN	―	CHF1.89B	29.73	4.57%	2.04%	-9.34%	-37.50%
YPSN	―	CHF4.28B	48.51	13.49%	0.71%	36.54%	11.60%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%